Date: 2016-01-05
Type of information: Resignation
Compound:
Company: Oxford Biomedica (UK)
Therapeutic area: Rare diseases - Genetic diseases
Type agreement: resignation
Action mechanism:
Disease:
Details: * On January 5, 2016, Oxford BioMedica , a leading gene and cell therapy group, announces that Dan Soland has been required to step down as a Non-Executive Director, due to his appointment as CEO of uniQure with immediate effect. Oxford BioMedica announced on 15 December 2015 that Lorenzo Tallarigo (experience includes: Intercept Pharmaceuticals, Genextra and Eli Lilly) has been appointed as Non-Executive Chairman of the Group and will join on 1 February 2016.
Financial terms:
Latest news:
